Table 4 Hazard ratios (95% confidence intervals) of depression, anxiety, and stress-related disorders during the year after cancer diagnosis in relation to pre-diagnostic exclusive use of aspirin, stratified analysis by different factors
Characteristics | Any exclusive aspirin use | Current aspirin | Low-dose aspirin | Long-term aspirin |
|---|---|---|---|---|
Calendar year at cancer diagnosis | ||||
2006–2009 | 0.82 (0.71–0.95) | 0.74 (0.63–0.87) | 0.82 (0.70–0.97) | 0.77 (0.65–0.92) |
2010–2013 | 0.93 (0.82–1.06) | 0.90 (0.78–1.04) | 0.93 (0.81–1.06) | 0.89 (0.77–1.03) |
P for interaction | 0.72 | 0.36 | 0.66 | 0.70 |
Sex | ||||
Male | 0.96 (0.83–1.11) | 0.92 (0.79–1.07) | 0.97 (0.83–1.12) | 0.90 (0.77–1.06) |
Female | 0.80 (0.70–0.92) | 0.74 (0.63–0.86) | 0.80 (0.69–0.93) | 0.77 (0.65–0.90) |
P for interaction | < 0.01 | < 0.01 | < 0.01 | 0.01 |
Age at cancer diagnosis, years | ||||
< 50 | 0.80 (0.42–1.54) | 0.80 (0.38–1.71) | 0.86 (0.44–1.71) | 0.87 (0.37–2.07) |
50–59 | 0.89 (0.65–1.21) | 0.79 (0.55–1.13) | 0.87 (0.63–1.20) | 0.71 (0.48–1.05) |
60–69 | 0.89 (0.74–1.08) | 0.88 (0.71–1.08) | 0.91 (0.75–1.11) | 0.84 (0.68–1.04) |
≥ 70 | 0.90 (0.79–1.03) | 0.84 (0.73–0.97) | 0.91 (0.79–1.04) | 0.89 (0.77–1.02) |
P for interaction | 0.82 | 0.92 | 0.93 | 0.32 |
Education level | ||||
Low | 0.89 (0.76–1.03) | 0.85 (0.72–1.01) | 0.89 (0.76–1.05) | 0.87 (0.74–1.03) |
Medium | 1.02 (0.87–1.20) | 0.93 (0.78–1.12) | 1.04 (0.88–1.23) | 0.96 (0.80–1.15) |
High | 0.67 (0.53–0.84) | 0.66 (0.51–0.85) | 0.63 (0.49–0.81) | 0.58 (0.45–0.77) |
P for interaction | 0.14 | 0.58 | 0.05 | 0.07 |
Marital status | ||||
Unmarried | 0.72 (0.54–0.96) | 0.76 (0.55–1.04) | 0.78 (0.58–1.06) | 0.72 (0.52–1.01) |
Married/registered partnership | 0.86 (0.74–0.99) | 0.79 (0.67–0.93) | 0.84 (0.72–0.98) | 0.78 (0.66–0.91) |
Divorced/separated | 0.97 (0.78–1.20) | 0.96 (0.75–1.22) | 0.98 (0.78–1.23) | 0.99 (0.77–1.26) |
Widow(er)/surviving partner | 0.97 (0.78–1.20) | 0.88 (0.69–1.11) | 0.98 (0.78–1.23) | 0.95 (0.75–1.20) |
P for interaction | 0.82 | 0.78 | 0.76 | 0.27 |
Occupation | ||||
Blue-collar | 0.89 (0.61–1.29) | 0.80 (0.52–1.23) | 0.88 (0.60–1.30) | 0.86 (0.56–1.32) |
White-collar | 0.80 (0.58–1.11) | 0.74 (0.51–1.07) | 0.77 (0.55–1.09) | 0.60 (0.40–0.91) |
Not working | 0.89 (0.80–1.00) | 0.85 (0.75–0.95) | 0.90 (0.81–1.01) | 0.87 (0.77–0.97) |
P for interaction | 0.93 | 0.92 | 0.86 | 0.84 |
Place of residence | ||||
East | 0.83 (0.71–0.97) | 0.76 (0.64–0.91) | 0.86 (0.73–1.01) | 0.79 (0.67–0.94) |
South | 0.93 (0.81–1.08) | 0.93 (0.79–1.10) | 0.93 (0.80–1.09) | 0.90 (0.76–1.06) |
North | 0.87 (0.69–1.12) | 0.73 (0.56–0.97) | 0.84 (0.65–1.09) | 0.80 (0.61–1.05) |
P for interaction | < 0.01 | < 0.01 | 0.01 | 0.01 |
Chronic disease scorec | ||||
1–3 | 0.91 (0.79–1.04) | 0.84 (0.72–0.98) | 0.91 (0.79–1.05) | 0.86 (0.74–1.01) |
> 3 | 0.87 (0.75–1.00) | 0.83 (0.71–0.97) | 0.88 (0.75–1.02) | 0.82 (0.70–0.96) |
P for interaction | 0.39 | 0.59 | 0.38 | 0.35 |
Cardiovascular disease | ||||
No | 0.95 (0.84–1.07) | 0.88 (0.76–1.01) | 0.97 (0.85–1.10) | 0.90 (0.78–1.03) |
Yes | 0.81 (0.68–0.95) | 0.79 (0.66–0.94) | 0.79 (0.66–0.93) | 0.78 (0.66–0.93) |
P for interaction | 0.01 | 0.12 | 0.01 | 0.07 |
Inflammatory musculoskeletal condition | ||||
No | 0.90 (0.81–1.01) | 0.84 (0.74–0.95) | 0.92 (0.82–1.03) | 0.86 (0.76–0.97) |
Yes | 0.82 (0.66–1.02) | 0.81 (0.64–1.03) | 0.76 (0.60–0.96) | 0.78 (0.61–0.99) |
P for interaction | 0.49 | 0.90 | 0.16 | 0.54 |
Inflammatory systemic disease | ||||
No | 0.88 (0.80–0.97) | 0.83 (0.74–0.93) | 0.89 (0.80–0.98) | 0.84 (0.75–0.94) |
Yes | 0.93 (0.51–1.69) | 0.85 (0.43–1.67) | 0.80 (0.41–1.57) | 0.75 (0.37–1.54) |
P for interaction | 0.88 | 0.85 | 0.47 | 0.58 |
Pain and fever | ||||
No | 0.88 (0.80–0.97) | 0.83 (0.74–0.92) | 0.88 (0.79–0.98) | 0.84 (0.75–0.94) |
Yes | 0.98 (0.52–1.84) | 1.04 (0.52–2.06) | 0.92 (0.47–1.80) | 0.61 (0.28–1.36) |
P for interaction | 0.90 | 0.66 | 0.98 | 0.42 |
Cancer stage | ||||
Localized limited | 0.78 (0.63–0.95) | 0.71 (0.56–0.89) | 0.79 (0.64–0.97) | 0.73 (0.58–0.92) |
Localized advanced | 1.06 (0.75–1.50) | 1.12 (0.77–1.64) | 0.95 (0.65–1.39) | 0.82 (0.55–1.24) |
Regional spread | 0.78 (0.61–0.99) | 0.72 (0.55–0.95) | 0.77 (0.60–1.00) | 0.73 (0.56–0.96) |
Distant metastasis | 1.01 (0.76–1.34) | 0.98 (0.72–1.33) | 1.10 (0.83–1.47) | 1.08 (0.80–1.47) |
P for interaction | 0.57 | 0.45 | 0.23 | 0.14 |
Cancer type | ||||
Prostate cancer | 0.94 (0.71–1.26) | 0.88 (0.64–1.20) | 0.93 (0.68–1.26) | 0.77 (0.56–1.07) |
Breast cancer | 0.74 (0.56–0.98) | 0.63 (0.46–0.87) | 0.73 (0.54–0.97) | 0.71 (0.52–0.98) |
Gastrointestinal cancer | 1.03 (0.84–1.27) | 1.05 (0.84–1.32) | 1.02 (0.82–1.27) | 1.03 (0.82–1.29) |
Lung cancer | 0.78 (0.58–1.05) | 0.70 (0.50–0.97) | 0.82 (0.61–1.12) | 0.73 (0.53–1.01) |
Skin cancer excl. Melanoma | 1.07 (0.66–1.74) | 0.89 (0.52–1.53) | 1.09 (0.65–1.84) | 1.19 (0.71–1.99) |
Melanoma | 0.56 (0.30–1.03) | 0.54 (0.28–1.05) | 0.45 (0.23–0.91) | 0.42 (0.20–0.89) |
Kidney and bladder | 0.86 (0.59–1.26) | 0.80 (0.52–1.23) | 0.85 (0.56–1.27) | 0.92 (0.61–1.39) |
Gynecologic cancer | 0.76 (0.52–1.12) | 0.83 (0.55–1.25) | 0.78 (0.52–1.16) | 0.68 (0.44–1.05) |
Hematological malignancies | 1.16 (0.82–1.66) | 1.25 (0.85–1.83) | 1.25 (0.87–1.80) | 1.18 (0.79–1.76) |
Other cancers | 0.80 (0.62–1.05) | 0.67 (0.49–0.91) | 0.83 (0.63–1.09) | 0.74 (0.55–1.01) |
P for interaction | 0.04 | 0.03 | 0.15 | 0.12 |